Sofinnova Investments, Inc. Puma Biotechnology, Inc. Transaction History

Sofinnova Investments, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$8.98 - $11.6 $3.1 Million - $4 Million	-344,917 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$9.38 - $13.63 $2.67 Million - $3.88 Million	-284,733 Reduced 45.22%	344,917 $3.35 Million
Q4 2020 Feb 16, 2021	BUY	$7.78 - $12.13 $1.2 Million - $1.86 Million	153,668 Added 32.28%	629,650 $6.46 Million
Q3 2020 Nov 13, 2020	SELL	$9.5 - $11.14 $6.86 Million - $8.04 Million	-721,648 Reduced 60.26%	475,982 $4.8 Million
Q2 2020 Aug 13, 2020	BUY	$7.01 - $13.24 $3.92 Million - $7.41 Million	559,604 Added 87.71%	1,197,630 $12.5 Million
Q1 2020 May 13, 2020	BUY	$6.28 - $14.57 $2.81 Million - $6.52 Million	447,399 Added 234.7%	638,026 $5.39 Million
Q4 2018 Feb 14, 2019	SELL	$20.07 - $46.7 $2.93 Million - $6.83 Million	-146,208 Reduced 43.41%	190,627 $3.88 Million
Q3 2018 Nov 15, 2018	BUY	$41.2 - $59.85 $11.3 Million - $16.5 Million	274,899 Added 443.84%	336,835 $15.4 Million
Q2 2018 Nov 15, 2018	BUY	$48.3 - $68.25 $2.68 Million - $3.79 Million	55,552 Added 870.18%	61,936 $3.66 Million
Q2 2018 Aug 14, 2018	BUY	$48.3 - $68.25 $308,347 - $435,708	6,384 New	6,384 $378,000

101

29M

50.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $137M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Sofinnova Investments, Inc., based on Form 13F filings with the SEC.

Stay updated on Sofinnova Investments, Inc. with notifications on news.